FDA: Page
-
Indian advisory board proposes waiving phase III for certain drugs
Drugs that have already been approved in "well regulated" markets like the U.S. and the E.U. would be granted a phase III waiver under the proposal.
By Nicole Gray • March 2, 2015 -
A biotech is bringing a new IUD to market—but the company's a nonprofit
San Francisco-based Medicines 360 plans to sustain itself through product sales with the help of its marketing partner, Actavis.
By Nicole Gray • March 2, 2015 -
EU approves first new chemical entity for Parkinson's in a decade
The drug is Newron Pharma's Xadago.
By Nicole Gray • Feb. 27, 2015 -
Gilead raking in billions off of foreign tax laws
In 2014, Gilead earned more in non-U.S. net profits than it recorded in non-U.S. sales.
By Nicole Gray • Feb. 27, 2015 -
Deep Dive
How 23andMe used rigorous clinical trials to win a landmark FDA authorization
And a D.C.-area physician dishes on his personal experiences with 23andMe's genetic testing kit.
By Nicole Gray • Feb. 26, 2015 -
Federal judge strikes down Maine's controversial prescription drug import law
PhRMA wins the first round of this legal battle. It's unclear if Maine will appeal the ruling.
By Nicole Gray • Feb. 26, 2015 -
FDA approves Actavis' QIDP-designated antibiotic combo
This is the fifth FDA-approved antibiotic designated as a Qualified Infectious Disease Product (QIDP).
By Sy Mukherjee • Feb. 26, 2015 -
UPDATE: Sanofi's likely blockbuster insulin Toujeo wins FDA approval
And now, the marketing battle begins.
By Sy Mukherjee • Feb. 25, 2015 -
Public Citizen requests FDA ban on certain antifungal meds
Advocates say that Ketoconazole pills' risks outweigh their benefits.
By Nicole Gray • Feb. 25, 2015 -
Novartis' Farydak wins FDA approval for multiple myeloma
But it comes with a black box warning and a REMS.
By Nicole Gray • Feb. 24, 2015 -
Lilly's long-acting insulin not ready for prime time
Despite positive phase 3 data on peglispro, the company's long-acting insulin-in-development, evidence of liver toxicity will delay FDA review at least two years—and potentially forever.
By Nicole Gray • Feb. 24, 2015 -
Compounding pharmacies chafe at FDA's disciplinary actions
The agency is determined to reign in compounders and impose more regulations after a well-publicized, fatal meningitis outbreak in 2012 and numerous cGMP violations.
By Nicole Gray • Feb. 23, 2015 -
Corgenix's 15-minute Ebola test approved by WHO
With successful positive identification of Ebola in 92% of patients in just 15 minutes, the ReEBOV Antigen Rapid Test can help identify the virus much more rapidly than conventional 24-hour tests.
By Nicole Gray • Feb. 23, 2015 -
FDA to review Pfizer's rare lung disease drug for women
Rapamune (sirolimus) is intended to treat lymphangioleiomyomatosis (LAM), a rare, progressive, often fatal lung disease that affects reproductive-aged women.
By Nicole Gray • Feb. 23, 2015 -
Holoclar makes history: Europe approves West's first stem-cell therapy
Chiesi, a privately held Italian company, has received approval in the EU for Holoclar for the treatment of eye burns.
By Nicole Gray • Feb. 23, 2015 -
In historic reversal, FDA approves 23andMe genetic test for Bloom Syndrome
And it could herald a sea change in the way the agency regulates the marketing of direct-to-consumer genetic testing.
By Sy Mukherjee • Feb. 20, 2015 -
New Jersey residents' parting gift to Roche: A lawsuit
As Roche prepares to depart its closed Clifton, NJ location to make way for a new private medical school, local residents are ready to initiate a class-action suit demanding environmental remediation.
By Nicole Gray • Feb. 20, 2015 -
Why FDA's label expansion for Celgene's Revlimid could foretell a global sales surge
Revlimid (lenalidomide) is now approved for use in newly diagnosed patients with multiple myeloma.
By Nicole Gray • Feb. 19, 2015 -
Shanghai official to serve 19 years over GSK bribery case
Huang Fengping, former deputy director for the Shanghai Municipal Commission of Health and Family Planning, has been sentenced to 19 years in jail by a Chinese court.
By Nicole Gray • Feb. 18, 2015 -
Sprout Pharma submits 'women's Viagra' for approval once again
After being FDA-rejected twice—and with a great deal of fanfare from supporters—Sprout Pharmaceuticals is resubmitting flibanserin for the treatment of female sexual desire.
By Nicole Gray • Feb. 18, 2015 -
FDA reopens conversation about controversial generic labeling rules
In 2013, the FDA proposed a controversial rule that could allow generic drug companies to update their labels with new safety information, even if that info isn't part of the reference product's label.
By Nicole Gray • Feb. 17, 2015 -
Deep Dive
3 charts that show why 2014 was a record year for US orphan drugs
From designation requests to product approvals, orphan drugs in the U.S. shattered records in 2014.
By Sy Mukherjee • Feb. 17, 2015 -
NAFTA patent spat rages on between Canada and Lilly
A battle that started two years ago rages on as Lilly accuses Canada of not protecting patent rights, while Canada calls Lilly's efforts to obtain additional patents for two of its antipsychotics "scattershot."
By Nicole Gray • Feb. 17, 2015 -
Eisai, Pfizer, and Novartis meds get FDA love over the long weekend
Who said Friday the 13th has to be unlucky, especially right before Valentine's Day?
By Sy Mukherjee • Feb. 13, 2015 -
AZ to settle Nexium kickback case for $7.9M
AstraZeneca was charged with paying millions to maintain exclusive status for Nexium on Medco's formulary of government-funded drugs.
By Nicole Gray • Feb. 13, 2015